<DOC>
	<DOCNO>NCT01178931</DOCNO>
	<brief_summary>The purpose study compare efficacy tolerability dydrogesterone vaginal progesterone , use luteal phase support . ( Initial start date January 2009 patient ' recruitment paper work , document , team organization , statistical pre-work action gain official approval Institutional Review Board . The recruitment start October 2010 continue October 2013 . )</brief_summary>
	<brief_title>Dydrogesterone Versus Intravaginal Progesterone Luteal Phase Support</brief_title>
	<detailed_description>The use gonadotropin-releasing hormone ( GnRH ) agonists ovarian stimulation , prevents premature surge luteal hormone ( LH ) , ultimately lead suppression pituitary gland high level estrogen observe induced cycle result inhibit effect implantation human embryo . The luteal support in-vitro-fertilization ( IVF ) cycle prolong use human chorion gonadotropin ( hCG ) and/or progesterone . Since note use hCG relate high risk onset ovarian hyperstimulation syndrome ( OHSS ) , progesterone nowadays product choice luteal support . Currently vaginal progesterone widely use , since classic oral progesterone result low bioavailability lower pregnancy rate intramuscular progesterone ( IM-P ) daily injection painful may cause abscess , inflammatory reaction local soreness . However , standard protocol luteal phase support establish ( i.e . optimal dosage , route duration ) . Dydrogesterone retroprogesterone good oral bioavailability . Oral administration clear advantage , due expect higher patient compliance well tolerability currently use vaginal IM-P. We hypothesize dydrogesterone efficacy vaginal progesterone well tolerability due less side effect .</detailed_description>
	<mesh_term>Dydrogesterone</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>routine ovulation induction protocol GnRH agonist less three prior IVF cycle least three aspirated oocyte BMI &lt; 35 kg/m2 age &lt; 45 year history dysfunctional uterine bleed acute urogenital disease recurrent miscarriage previous allergic reaction progesterone product</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>IVF</keyword>
	<keyword>luteal phase support</keyword>
	<keyword>oral progesterone</keyword>
	<keyword>vaginal progesterone</keyword>
	<keyword>pregnancy rate</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
</DOC>